Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi

Atupele Kapito-Tembo, Steven R Meshnick, Michaël Boele van Hensbroek, Kamija Phiri, Margaret Fitzgerald, Victor Mwapasa, Atupele Kapito-Tembo, Steven R Meshnick, Michaël Boele van Hensbroek, Kamija Phiri, Margaret Fitzgerald, Victor Mwapasa

Abstract

Background: Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown. We examined effectiveness of CTX with or without SP-IPTp versus SP-IPTp at reducing malaria parasitemia and anemia.

Methods: From 2005 to 2009, we conducted a cross-sectional study of HIV-infected pregnant women at Thyolo Hospital, Malawi. Blood was tested for malaria parasitemia and anemia (hemoglobin<11 g/dl). Data were collected on use of anti-malaria interventions and other risk factors. CTX prophylaxis policy for HIV-infected pregnant women was introduced in 2007, but implementation problems resulted in some women receiving both CTX and SP-IPTp.

Findings: We enrolled 1,142 women, of whom 1,121 had data on CTX and/or SP-IPTp intake. Of these, 49.7%, 29.8%, and 15.4% reported taking SP-IPTp only, CTX only and SP-IPTp plus CTX, respectively. Compared with women taking SP-IPTp, those taking SP-IPTp plus CTX and CTX were less likely to have malaria parasitemia (OR, [95%CI]: 0.09, [0.01-0.66] and 0.43, [0.19-0.97], respectively) or anemia (PR, [95% CI]: 0.67, [0.54-0.83] and 0.72, [0.61-0.83], respectively).

Conclusion: In HIV-infected pregnant women, daily CTX was associated with reduced malaria parasitemia and anemia compared with SP-IPTp. CTX plus SP-IPTp was associated with further reduction in malaria parasitemia but toxicity was not fully assessed.

Figures

Figure 1.
Figure 1.
Prevalence of malaria with 95% confidence interval by antimalarial drug intake in HIV-infected pregnant women at Thyolo District Hospital, Malawi (2005–2009).

References

    1. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.
    1. Perrault SD, Hajek J, Zhong K, et al. Human immunodeficiency virus co-infection increases placental parasite density and transplacental malaria transmission in Western Kenya. Am J Trop Med Hyg. 2009;80:119–25.
    1. Verhoeff FH, Brabin BJ, Hart CA, Chimsuku L, Kazembe P, Broadhead RL. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health. 1999;4:5–12.
    1. van Eijk AM, Ayisi JG, ter Kuile FO, et al. HIV increases the risk of malaria in women of all gravidities in Kisumu, Kenya. AIDS. 2003;17:595–603.
    1. ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg. 2004;71:41–54.
    1. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: Recommendations for a public health approach. Geneva, Switzerland: World health Organization; 2006.
    1. World Health Organization. Geneva, Switzerland: World health Organization;; 2006. Guidelines for the treatment of malaria. 1st ed.
    1. Newman PM, Wanzira H, Tumwine G, et al. Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J. 2009;8:254.
    1. Meshnick SR, Mwapasa V, Rogerson SJ. Protecting pregnant women from malaria in areas of high HIV infection prevalence. J Infect Dis. 2006;194:273–5.
    1. Briand V, Badaut C, Cot M. Placental malaria, maternal HIV infection and infant morbidity. Ann Trop Paediatr. 2009;29:71–83.
    1. Hamel MJ, Greene C, Chiller T, et al. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg. 2008;79:320–30.
    1. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007;21:2059–66.
    1. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: A prospective cohort study. Lancet. 2006;367:1256–61.
    1. Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis. 2005;192:1823–9.
    1. World Health Organization. Malaria and HIV interactions and their implications for public health policy. Geneva, Switzerland: World Health Organization; 2005.
    1. Government of Malawi Ministry of Health. Treatment of AIDS: Guidelines for the use of antiretroviral therapy in Malawi. 2nd ed. Lilongwe, Malawi: Malawi Ministry of Health; 2006.
    1. Government of Malawi Ministry of Health. National guidelines for the diagnosis, treatment and prevention of malaria in Malawi. Lilongwe, Malawi: Malawi Ministry of Health; 2007.
    1. Gilles HM. Diagnostic methods in malaria. In: Bruce-Chwatt LJ, Gilles HM, Warrell DA, editors. Essential malariology. 3rd ed. London, UK: Edward Arnold; 1993. pp. 78–98.
    1. Taylor SM, Juliano JJ, Trottman PA, et al. High-throughput pooling and real-time PCR-based strategy for malaria detection. J Clin Microbiol. 2010;48:512–9.
    1. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37–48.
    1. Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: An application to birth defects epidemiology. Am J Epidemiol. 2002;155:176–84.
    1. Gwatkin DR, Rutstein S, Johnson K, Suliman E, Wagstaff A, Amouzou A. Socio-economic differences in health, nutrition, and population: Malawi 1992, 2000. Washington, DC: World Bank; 2000. Report No.: 39450.
    1. Vyas S, Kumaranayake L. Constructing socio-economic status indices: How to use principal components analysis. Health Policy Plan. 2006;21:459–68.
    1. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: An empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21.
    1. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162:199–200.
    1. Petersen MR, Deddens JA. A comparison of two methods for estimating prevalence ratios. BMC Med Res Methodol. 2008;8:9.
    1. Coutinho LM, Scazufca M, Menezes PR. Methods for estimating prevalence ratios in cross-sectional studies. Rev Saude Publica. 2008;42:992–8.
    1. Bello GA, Chipeta J, Aberle-Grasse J. Assessment of trends in biological and behavioural surveillance data: Is there any evidence of declining HIV prevalence or incidence in Malawi? Sex Transm Infect. 2006;82:i9–13.
    1. Filler SJ, Kazembe P, Thigpen M, et al. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infect Dis. 2006;194:286–93.
    1. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998;59:813–22.
    1. Hamer DH, Mwanakasale V, Macleod WB, et al. Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. J Infect Dis. 2007;196:1585–94.
    1. Gill CJ, Macleod WB, Mwanakasale V, et al. Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. J Infect Dis. 2007;196:1577–84.
    1. Bwijo B, Kaneko A, Takechi M, et al. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop. 2003;85:363–73.
    1. Green MD, van Eijk AM, ter Kuile FO, et al. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J Infect Dis. 2007;196:1403–8.
    1. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: A systematic review. JAMA. 2007;297:2603–16.
    1. Petersen E. In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethoxazole, singly and in combination. Trans R Soc Trop Med Hyg. 1987;81:238–41.
    1. Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet. 2001;358:1066–7.
    1. Martin DC, Arnold JD. Treatment of acute falciparum malaria with sulfalene and trimethoprim. JAMA. 1968;203:476–80.
    1. Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety and toxicity of sulfadoxine/pyrimethamine: Iimplications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 2007;30:481–501.
    1. Siega-Riz AM, Savitz DA, Zeisel SH, Thorp JM, Herring A. Second trimester folate status and preterm birth. Am J Obstet Gynecol. 2004;191:1851–7.
    1. Molloy AM, Kirke PN, Brody LC, Scott JM, Mills JL. Effects of folate and vitamin B12 deficiencies during pregnancy on fetal, infant, and child development. Food Nutr Bull. 2008;29:S101–15.
    1. Folate and vitamin B12 deficiencies: Pproceedings of a WHO technical consultation held 18–21 October, 2005, in Geneva, Switzerland. Introduction. Food Nutr Bull. 2008;29:S3–4.
    1. Heimpel H, Raghavachar A. Hematological side effects of co-trimoxazole. Infection. 1987;15:S248–53.
    1. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–14.
    1. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol. 2001;153:961–8.
    1. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: A population based case-control study. Reprod Toxicol. 2001;15:637–46.
    1. Walter J, Mwiya M, Scott N, et al. Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts. J Infect Dis. 2006;194:1510–8.
    1. Nguyen-Dinh P, Steketee RW, Greenberg AE, Wirima JJ, Mulenda O, Williams SB. Rapid spontaneous postpartum clearance of Plasmodium falciparum parasitaemia in African women. Lancet. 1988;2:751–2.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다